The battle against emerging antibiotic resistance: Should fluoroquinolones be used to treat children?

Clinical Infectious Diseases

Volumn 35, Issue 6, 2002, Pages 721-727

  Mandell, Lionel A ^a   Peterson, Lance R ^c   Wise, Richard ^f   Hooper, David ^d   Low, Donald E ^b   Schaad, Urs B ^g   Klugman, Keith P ^e,h   Courvalin, Patrice ⁱ  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e EMORY UNIVERSITY   (United States)

^f CITY HOSPITAL   (United Kingdom)

^g UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^h MRC   (South Africa)

ⁱ INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; BACTERIAL COLONIZATION; CARDIOTOXICITY; CARTILAGE DEGENERATION; DRUG MISUSE; GENE EXPRESSION; GENE MUTATION; HEART ARRHYTHMIA; HOMOLOGOUS RECOMBINATION; HUMAN; LONG QT SYNDROME; MOUTH FLORA; MULTIDRUG RESISTANCE; NASOPHARYNX; PHENOTYPE; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SEIZURE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG DESIGN; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; FLUOROQUINOLONES; FORECASTING; HUMANS; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037105789     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/341900     Document Type: Review

References (90)

1. Ten great public health achievements- United States, 1990-1999
2. Chain E: An enzyme from bacteria able to destroy penicillin
3. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
4. Antibiotic resistance in Spain: What can be done?
5. Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in chnicalisolates of antibiotic-resistant bacteria
6. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms
7. The biopesticide Paenibacillus popilliae has a common vancomycin resistance gene cluster to the enterococcal vanA vancomycin resistance gene cluster
8. Antibiotic resistance: Microbial adaptation and evolution
9. Recovery of resistance factors from a drug-free community
10. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci
11. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
12. The challenges of emerging infectious diseases: Development and spread of multiply-resistant bacterial pathogens
13. Epidemiology of drug resistance: Implications for a post-antimicrobial era
14. Bacterial gene transfer by natural genetic transformation in the environment
15. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone
16. Genetics of oxacillin resistance in clinical isolates of Streptococcus pneumoniae that are oxacillin resistant and penicillin susceptible
17. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae
18. Evolution of penicillin resistance in Streptococcus pneumoniae: The role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae
19. Minimizing potential resistance: The molecular view
20. United States geographic bacteria susceptibility patterns
21. Emergence of multiply resistant pneumococci
22. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States
23. Transposable multiple antibiotic resistance in Streptococcus pneumoniae
24. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria
25. Nomenclature of major antibiotic-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network
26. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000
27. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
28. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland
29. Treatment of bone, joint, and soft tissue infections with oral ciprofloxacin
30. Treatment of skin and soft tissue infections with oral ciprofloxacin
31. Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males
32. Fluoroquinolone antimicrobial agents
33. Therapy effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis
34. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy
35. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults
36. Fluoroquinolone antimicrobial agents
37. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
38. Practice guidelines for the management of community-acquired pneumonia in adults
39. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
40. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children
41. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae
42. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
43. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HW seroprevalence
44. Breakthrough bacteremia and meningitis during treatment parenterally with cephalosporins for pneumococcal pneumonia
45. Pneumonia treatment failure associated with highly resistant pneumococci
46. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
47. Meningitis and pnuemonia due to novel multiply resistant pneumococci
48. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae
49. Chemistry and mechanism of action of the quinolone antibacterial
50. Development of erythromycin-resistant pneumococcal endocarditis in a patient receiving erythromycin for community-acquired pneumonia
51. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux
52. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin
53. Streptococcus pneumoniae resistance to fluoroquinolones
54. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study
55. Ofloxacin in juvenile non-human primates and rats: Arthropathia and drug plasma concentrations
56. Quinolone-induced arthropathy in the neonatal mouse: Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin
57. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone
58. Integrins: Versatility, modulation and signaling in cell adhesion
59. Quinolone arthropathy in animals versus children
60. Toxicity of quinolone antimicrobial agents
61. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model
62. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
63. Tolerability of fluoroquinolone antibiotics: Past, present and future
64. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
65. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel
66. Association of penicillin-resistant pneumococci with residence in a pediatric chronic care facility
67. Invasive penicillin-resistant pneumococcal infections: A prevalence and historical cohort study
68. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal
69. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross-sectional prevalence study
70. Macrolide resistance among invasive Streptococcus pneumoniae isolates
71. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones
72. Use of fluoroquinolones in pediatrics: Consensus report of an International Society of Che-motherapy commission
73. Use of the quinolones in pediatrics
74. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis
75. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
76. Oral ciprofloxacin versus intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety using ultrasonography and magnetic resonance imaging
77. Using quinolones in urinary tract infections in children
78. Evaluation of norfloxacin in the pediatric field
79. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis
80. Oral ciprofloxacin vs intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children
81. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: Preliminary experience in 21 children
82. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: A comparison of ciprofloxacin and rifampicin
83. Use of fluoroquinolones as prophylaxis agents in patients with neutropenia
84. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients
85. Ciprofloxacin in neonatal Enterobacter doacae septicaemia
86. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: Report of 12 cases and review
87. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: Experiences from the south Swedish pneumococcal intervention project
88. Comparative tolerability of the newer fluoroquinolone antibacterials
89. Outcomes after judicious antibiotic use for respiratory tract infections in a private pediatric practice
90. New uses for new and old quinolones and the challenge of resistance